Emerging diabetes drugs consider beta cell mass and function as an important targe.

Eating oily fish containing docosahexaenoic acid and eicosapentaenoic acid at least once a week appears to decrease the risk of developing wet age-related macular degeneration by half, according to a large population-based study.

Individuals who have a genetic mutation associated with high body mass index (BMI) may be able to offset their increased risk for obesity through physical activity, according to the results of a study.

Sometimes a report comes out that just makes no sense. Recently the US Preventive Services Task Force (USPSTF) has issued a statement that limited evidence exists to recommend screening adults for type 2 diabetes. Limited evidence? How ridiculous is this? Give us your comment!

High Protein Diets- Do They Work?? Kelli Culler, Doctor of Pharmacy Candidate, University of Florida, has found some interesting information after researching a little seen article. Click here to learn what she found out.

The once a day drug, liraglutide, is a laboratory-made version of glucagon-like peptide-1 (GLP-1), a hormone produced by the body. Several members of the GLP-1 family are in clinical trials, and one (Byetta) already has been approved by the U.S. Food and Drug Administration.

Denmark’s Novo Nordisk, the world’s biggest maker of insulin, on Friday said it expected to start a Phase III trial for its drug candidate liraglutide in obesity before the end of this year.

Treatment showed a 2.9% drop in A1c and a 27.5lb weight loss in 30 weeks.

Takeda Pharmaceutical Co said last Wednesday it had applied for approval to market in the United States the DPP-4 inhibitor Alogliptin and the Actos diabetes drugs in a single tablet for the treatment of type 2 diabetes.

First in class drug stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism.